CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 194 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07325955
NCT07325955N/ACompleted

Effect of Long Term Trimetazidine Treatment on Myocardial Final Fibrosis for Acute Myocardial Infarction

Chinese PLA General Hospital·observational·Posted Jan 8, 2026·Updated Jan 8, 2026

In Brief

An observational study for ST Elevation Myocardial Infarction (STEMI). Completed, enrolled 194 participants across 1 site.

Detailed Summary

Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real world clinical practice. In this observational study, we investigated the effect of long-term treatment with trimetazidine on the final extent of myocardial fibrosis measured by cardiac magnetic resonance 6 months after infarction in real world clinical practice.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedJan 8, 2026
Enrollment StartOct 1, 2020
Primary CompletionJul 1, 2024
Study CompletionDec 1, 2024
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 6 months ago